Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
SUMMIT THERAPEUTICS - CORPORATE | GBp160 vs 155 (+514%) Summit 2018 results – Shifting to superior antibiotics FY2019 financial highlights - cash runway into 2020 Refocused strategy on novel mechanism antibiotics Significantly undervalued with a phase 3 C.diff candidate
In this era of growing threats to health and medical practice coming from ever more resistant super strains of antibiotic-resistant bacterial, it is timely that Summit Therapeutics is driving new mechanism antibiotics into clinical development. Summit is a leading, Oxford-based innovative biotech company, focused on developing novel, best-in-class antibiotics with new mechanisms of action specific for bacteria such as C.difficile, N.gonorrhoea, and others (ESKAPE pathogens). Summit’s novel ant...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.